Company intelligence / Profile preview

Equinox Ophthalmic

California, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Equinox Ophthalmic has developed the Multi-Pressure Dial (MPD) goggle system that applies localized periocular negative pressure to lower intraocular pressure; a prospective randomized controlled trial in suspected glaucoma, ocular hypertension, and open-angle glaucoma showed that 89.7% of treated eyes achieved ≥20% IOP reduction at 90 days versus 3.4% of controls, with lid and periorbital edema as the most common adverse events, supporting safety and efficacy but requiring longer-term data.[1]

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Equinox Ophthalmic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equinox Ophthalmic.

Explore the full profile